Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- Drug: cyclophosphamide, vincristine, prednisone, dacarbazineDrug: cyclo, vcr, pred, dacarb,etop and doxo
- Registration Number
- NCT02684708
- Lead Sponsor
- University of Giessen
- Brief Summary
The EuroNet-PHL-C2 trial is an international, multicentre, randomised controlled trial with the aims to reduce the indication for radiotherapy in newly diagnosed patients with classical Hodgkin lymphoma without compromising cure rates and to investigate a chemotherapy intensification randomisation in intermediate and advanced classical Hodgkin lymphoma to compensate for reduction in radiotherapy.
- Detailed Description
EuroNet-PHL-C2 is a comprehensive treatment strategy for all first line classical Hodgkin Lymphoma (cHL) patients under 18 years (under 25 years in UK, Italy and France). The overall strategy is risk stratified (defining chemotherapy) and response adapted (defining radiotherapy) to tailor the amount of treatment to the individual patient and decrease long term complications.
* Radiotherapy indication will be restricted. Patients with a negative PET scan after two cycles of OEPA chemotherapy (Early Response Assessment - ERA) will not receive radiotherapy. The threshold for negative PET scan at ERA shifts from the previously used Deauville 1 and 2 = negative (as in the C1 trial) to Deauville 1, 2 and 3 = negative, thereby increasing the number of negative patients without indication for RT.
* Chemotherapy Randomisation
All intermediate (TL-2) and advanced stage (TL-3) patients will be randomised between respectively 2 or 4 standard COPDAC-28 or intensified DECOPDAC-21 consolidation chemotherapy cycles. To avoid delayed consolidation, randomisation has to be performed before ERA and as soon as the TL-assignment is confirmed by central review. Therefore two randomised sub-studies arise based on the ERA PET response:
Patients with adequate response at ERA do not receive radiotherapy - a randomised controlled chemotherapy comparison to show that intensified DECOPDAC-21 consolidation chemotherapy improves EFS as compared to standard COPDAC-28
Patients with inadequate response at ERA - a randomised controlled chemotherapy-radiotherapy comparison - to show that DECOPDAC-21 combined with radiotherapy restricted to sites that remain FDG-PET positive at the end of all chemotherapy (Late response assessment - LRA) has comparable EFS compared to COPDAC-28 plus standard involved node radiotherapy as in the C1 trial.
* Risk stratification is refined Former treatment groups (TG) of the EuroNet-PHL-C1 trial are reassigned into treatment levels (TL) by shifting early stage patients (former TG-1) with risk factors into TL-2.
* Semi-quantitative 'qPET' Results of semi-quantitative qPET are formally integrated into the response assessment.
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 2200
- histologically confirmed primary diagnosis of classical Hodgkin's lymphoma
- patients under 18 years of age on the date of written informed consent. In specialized Teenage and Young Adult (TYA) units in France, Italy and UK patients up to under 25 years of age can also be enrolled. Lower age limits will be country specific according to national laws or formal insurance requirements that may preclude very young patients.
- written informed consent of the patient and/or the patient's parents or guardian according to national laws
- negative pregnancy test within 2 weeks prior to starting treatment for female patients with childbearing potential
- prior chemotherapy or radiotherapy for other malignancies
- pre-treatment of Hodgkin's lymphoma (except for 7-10 days steroid pre-phase of a large mediastinal tumour)
- diagnosis of lymphocyte-predominant Hodgkin's lymphoma
- other (simultaneous) malignancies
- contraindication or known hypersensitivity to study drugs
- severe concomitant diseases (e.g. immune deficiency syndrome)
- known HIV-positivity
- residence outside the participating countries where long term follow-up cannot be guaranteed
- pregnancy and/or lactation
- patients who are sexually active and are unwilling to use adequate contraception during therapy and for one month after last trial treatment
- current or recent (within 30 days prior to date of written informed consent) treatment with another investigational drug or participation in another interventional clinical trial
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description COPDAC-28 cyclophosphamide, vincristine, prednisone, dacarbazine cyclophosphamide, vincristine, prednisone, dacarbazine; cyclophosphamide 500 mg/m2, per infusion on day 1 + 8; vincristine 1.5 mg/m2 intravenously (capping dose 2 mg) on day 1 + 8 and prednisone 40 mg/m2/day by mouth divided into 3 doses (capping dose 80 mg/day) on day 1 - 15 and dacarbazine 250 mg/m2 infusion on day 1 - 3 DECOPDAC-21 cyclo, vcr, pred, dacarb,etop and doxo patients with intermediate and advanced stages will be randomized after the induction therapy to receive either COPDAC-28 standard consolidation or the intensified DECOPDAC-21. cyclophosphamide dose augmented to 625 mg/m2 and adminstered per infusion on day 1 and day 2; vincristine dose not changed; prednisone 40 mg/m2/day by mouth on day 1 - 8 (no capping dose prescribed), i.e. dose-reduction; dacarbazine dose not changed; etoposide infusion100 mg/m2/day on day 1 - 3 and doxorubicine 25 mg/m2 per infusion on day 1as additional drugs in comparison to active comparator; cycle is administered as 21 days instead of 28 days-cycle for intensification
- Primary Outcome Measures
Name Time Method Event-free survival 5 years Time from treatment start until relapse/progression, secondary malignancy or death
- Secondary Outcome Measures
Name Time Method Overall survival 5 years Time from treatment start until death
Progression-free survival 5 years Time from treatment start until relapse/progression or death
Time from last dose of prednisone/prednisolone in OEPA to start of the first consolidation cycle 5 years Quality of chemotherapy delivery
CTC (common toxicity criteria) grading during any individual treatment element including assessment of osteonecrosis 5 years Toxicity assessment according to CTCAE v4.0
Time from last day of chemotherapy to first day of radiotherapy in patients with radiotherapy indication 5 years Quality of chemo-and radiotherapy delivery
Time from day of PET imaging until decision on response category at ERA or LRA, respectively 5 years Quality of Imaging (CT,MRI and PET-CT) acquisition,
Trial Locations
- Locations (19)
St. Anna Kinderspital
🇦🇹Wien, Austria
Department of Medical Oncology Oslo University Hospital
🇳🇴Oslo, Norway
Pediatric Radiotherapy and Youth Area Unit C.R.O. - Centro di Riferimento Oncologico IRCCS
🇮🇹Aviano, Italy
Justus Liebig University of Giessen
🇩🇪Giessen, Germany
Princess Máxima Center for pediatric oncology
🇳🇱Utrecht, Netherlands
Starship Blood and Cancer Centre, Starship Children's Hospital
🇳🇿Auckland, New Zealand
Sección de Onco-HematologÃa Pediátrica Hospital Universitario Virgen Macarena y Virgen del RocÃo
🇪🇸Sevilla, Spain
Tel Aviv University Schneider Children's Medical Center of Israel The Rina Zaizov Pediatric Hematology Oncology Division
🇮🇱Petach Tikva, Israel
CHUV - Centre Hospitalier Universitaire Vaudois = LS, Départment femme - meré - enfant, Service de pédiatrie, Unité d'hématologie-oncologie pédiatrique
🇨ðŸ‡Lausanne, Switzerland
Paediatric haemato-oncology, University Hospitals of Leuven
🇧🇪Leuven, Belgium
Head of Department of Pediatric Oncology and Hematology, Polish-American Pediatric Institute, Jagiellonian University Medical Faculty
🇵🇱Kraków, Poland
University College London Hospitals
🇬🇧London, United Kingdom
Clinic of Pediatric Oncology University Children's Hospital
🇸🇰Bratislava, Slovakia
Pediatric Hematology & Oncology Children´s University Hospital
🇸🇪Uppsala, Sweden
Service d'Oncohématologie, Hopital d'Ènfants Armand Trousseau
🇫🇷Paris, France
Royal Children's Hospital and Monash Medical Centre Royal Children's Hospital
🇦🇺Victoria Park, Australia
Dpt. of Pediatric Hematology and Oncology, Faculty Hospital Motol
🇨🇿Prague, Czechia
Department of Pediatric Hematology/Oncology (5054) The Child and Youth Clinic, University Hospital of Copenhagen
🇩🇰Copenhagen, Denmark
Our Lady's Children's Hospital, Crumlin
🇮🇪Dublin, Ireland